Kenvue Inc. (KVUE)

Kenvue is the world's largest pure-play consumer health company by revenue, generating $15.4 billion in net sales in 2023, operating across more than 165 countries with a legacy exceeding 135 years. The company was separated from Johnson & Johnson through an IPO in May 2023 and a subsequent exchange offer completed in August 2023, becoming fully independent, with J&J retaining approximately 9.5% ownership. Kenvue operates through three reportable segments: Self Care (featuring brands like Tylenol, Motrin, Benadryl, Zyrtec, and Nicorette), Skin Health and Beauty (including Neutrogena, Aveeno, and Rogaine), and Essential Health (with brands such as Listerine, Johnson's, BAND-AID, and Stayfree).

The company's portfolio spans product categories including pain care, cough/cold/allergy, digestive health, smoking cessation, skin and hair care, oral care, baby care, women's health, and wound care. Geographically balanced across North America, APAC, EMEA, and LATAM, roughly half of net sales originate outside North America. Kenvue emphasizes a digital-first marketing approach, with digital spend rising from 44% of media spend in 2019 to approximately 73% in 2023, and invests heavily in R&D through roughly 1,500 scientists and specialists across global innovation hubs.

Its supply chain combines in-house manufacturing (over half of 2023 production volume) with third-party manufacturing and distribution partnerships to ensure flexibility and reliability. The company faces competition from major CPG and pharmaceutical companies including Haleon, Procter & Gamble, Reckitt Benckiser, Beiersdorf, L'Oréal, Unilever, Colgate-Palmolive, and Kimberly-Clark, as well as private-label and niche brands. Kenvue's ESG strategy, branded the Healthy Lives Mission, focuses on three pillars—Healthy People, Healthy Planet, and Healthy Practice—covering areas like diversity and inclusion, product safety, climate change, sustainable packaging, and ethical business practices.

As of December 31, 2023, the company employed approximately 22,000 people globally, with a workforce roughly evenly split by gender and notable diversity representation in leadership. Kenvue relies on trademarks, patents, and licensed intellectual property (including temporary use of J&J branding) to protect its business, and operates under extensive regulatory oversight from agencies such as the FDA, FTC, CPSC, OSHA, EPA, and DEA in the U.S., along with comparable regulatory bodies internationally, particularly in the EU and China.